Verity Pharmaceuticals presents news that is not only specific to our corporation but also lists important information that is relevant to the disease categories we do business in.




Verity Pharmaceuticals acquires Pendopharm’s rights to commercialize ZEULIDE DEPOT™ for the Canadian oncology community – June 27, 2019

IVOZFO™ (fosfomycin for injection), a novel ‘first in class’ iv antibiotic approved for use in Canada. IVOZFO provides a new option for hard-to-treat infections, including multi-drug resistant superbugs – May 1, 2019

Verity Pharmaceuticals completes new drug submission to Health Canada for BCG bladder cancer treatment – November 1, 2018

Verity announces a licensing agreement for mitomycin with Vygoris, UK – November 1, 2018

Health Canada grants intravenous fosfomycin priority review status – July 16, 2018

Recent publication: intravenous fosfomycin potential in Canada and it’s role with MDR pathogens – July 11, 2018

Verity announces licensing agreement with Infectopharm to bring novel anti-infective to Canada – March 21, 2018

Verity Pharmaceuticals announces the appointment of Allan Silber to the board of directors – December 18, 2017

Verity Pharmaceuticals appoints scientific advisory board – September 4, 2016

Appointment of Mr. R. Rieder as chairman – July 5, 2016